

Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on May 28, 2026 | For discussion with your oncologist

TRIAL

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT ID: NCT07015190 Phase: PHASE3 Sponsor: IDEAYA Biosciences Status: Recruiting

SUMMARY

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

KEY ELIGIBILITY CRITERIA

- * Primary non-metastatic uveal melanoma
- * Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements
- * ECOG 0 or 1
- * Adequate organ function
- * Previous treatment for UM
- * Evidence of metastatic UM
- * Attributes that necessitate enucleation regardless of response to therapy
- * Evidence of progressive secondary underlying ocular disease that would confound longitudinal VA assessments
- * Presence of a malignant disease other than the one being treated in this study

ENROLLMENT CONTACT

Odette Houghton, MD Principal Investigator

Mayo Clinic Scottsdale - PPDS
Scottsdale, Arizona, United States

Total sites: 94 | 25 currently recruiting